133 related articles for article (PubMed ID: 17345605)
21. [A case of acute disseminated encephalomyelitis associated with Epstein-Barr virus reactivation during infliximab therapy].
Ueda M; Tateishi T; Shigeto H; Yamasaki R; Ohyagi Y; Kira J
Rinsho Shinkeigaku; 2010 Jul; 50(7):461-6. PubMed ID: 20681262
[TBL] [Abstract][Full Text] [Related]
22. Latent viral infections in young patients with inflammatory diseases treated with biological agents: prevalence of JC virus genotype 2.
Comar M; Delbue S; Lepore L; Martelossi S; Radillo O; Ronfani L; D'Agaro P; Ferrante P
J Med Virol; 2013 Apr; 85(4):716-22. PubMed ID: 23364870
[TBL] [Abstract][Full Text] [Related]
23. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
24. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
25. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
[TBL] [Abstract][Full Text] [Related]
27. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
28. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.
Ueno Y; Tanaka S; Shimamoto M; Miyanaka Y; Hiyama T; Ito M; Kitadai Y; Yoshihara M; Sumii M; Chayama K
Dig Dis Sci; 2005 Jan; 50(1):163-6. PubMed ID: 15712655
[No Abstract] [Full Text] [Related]
29. [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea].
Choi KD; Song HJ; Kim JS; Jung HC; Song IS
Korean J Gastroenterol; 2005 Jul; 46(1):48-55. PubMed ID: 16030404
[TBL] [Abstract][Full Text] [Related]
30. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
31. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
32. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
[TBL] [Abstract][Full Text] [Related]
33. Multiple latent viruses reactivate in astronauts during Space Shuttle missions.
Mehta SK; Laudenslager ML; Stowe RP; Crucian BE; Sams CF; Pierson DL
Brain Behav Immun; 2014 Oct; 41():210-7. PubMed ID: 24886968
[TBL] [Abstract][Full Text] [Related]
34. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
[TBL] [Abstract][Full Text] [Related]
35. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
[TBL] [Abstract][Full Text] [Related]
36. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
Mendoza JL; García-Paredes J; Cruz Santamaria DM; Lana R; Ramírez Fernández E; Rodríguez Asteaga E; Díaz-Rubio M
Rev Esp Enferm Dig; 2002 May; 94(5):269-79. PubMed ID: 12474335
[TBL] [Abstract][Full Text] [Related]
37. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
[TBL] [Abstract][Full Text] [Related]
38. Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis.
Pillet S; Jarlot C; Courault M; Del Tedesco E; Chardon R; Saint-Sardos P; Presles E; Phelip JM; Berthelot P; Pozzetto B; Roblin X
Inflamm Bowel Dis; 2015 Jul; 21(7):1580-6. PubMed ID: 25933392
[TBL] [Abstract][Full Text] [Related]
39. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
40. The link between VLA-4 and JC virus reactivation.
Monaco MC; Major EO
Expert Rev Clin Immunol; 2012 Jan; 8(1):63-72. PubMed ID: 22149341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
